Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Complement-Mediated Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for C3/C3b/C3c drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | C3/C3b ECD-Fc / Fragment Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified, Native Conformation. |
View C3 Products |
| Gene Delivery | C3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View C3 Products |
| Benchmark Ab | Anti-C3/C3b (Sequence of Pegcetacoplan/Compstatin analogs) Recombinant positive control. |
View C3 Products |
| Validator | C3 siRNA Set For knockdown verification and pathway analysis. |
View C3 Products |
| Related Target A | C5 Downstream terminal complement pathway effector. |
View C5 Products |
| Related Target B | CFB Alternative pathway amplification loop partner. |
View CFB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intact vs. Cleavage Fragment Specificity | Highly purified, distinct C3, C3b, and C3c recombinant proteins strictly verified by mass spectrometry and SDS-PAGE. |
| High Serum Target Burden Simulation | Concentrated, carrier-free formulations available for high-dose binding assays and viscosity screening. |
| Spontaneous Activation in Assays | Endotoxin strictly controlled (<1EU/ug) and functionally silent preparations to prevent false-positive assay activation. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity for toxicology and bridging studies. |
Live C3/C3b/C3c/CO3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for C3 therapeutics is intensifying, with major players shifting focus from traditional mAbs to cyclic peptides, siRNA, and gene therapies. As first-generation therapies (such as pegcetacoplan) achieve commercial success in the clinic for Paroxysmal Nocturnal Hemoglobinuria (PNH) and Geographic Atrophy (GA), the next wave of R&D is targeting optimal half-life extension, intravitreal delivery optimization, and precision targeting of specific C3 cleavage fragments (C3b/iC3b) to leave basal C3 immune surveillance intact.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Cyclic Peptides | Apellis (Pegcetacoplan) | PNH, Geographic Atrophy, C3G | Affinity/Kinetics (Need highly pure, intact C3 protein) |
| Monoclonal Antibodies | Novartis, Roche | IgA Nephropathy, aHUS | Fragment Specificity (Need distinct C3 vs C3b/C3c antigens) |
| siRNA / Oligos | Alnylam, Ionis | Systemic Complement Diseases | Knockdown Validation (Need Sequence Verified C3 controls) |
| Gene Therapy / AAV | Hemera Biosciences | Dry AMD / Macular Degeneration | Expression Monitoring (Need Benchmark Binding Reagents) |